1. Home
  2. RCKT vs VYX Comparison

RCKT vs VYX Comparison

Compare RCKT & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • VYX
  • Stock Information
  • Founded
  • RCKT 1999
  • VYX 1881
  • Country
  • RCKT United States
  • VYX United States
  • Employees
  • RCKT N/A
  • VYX N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • VYX
  • Sector
  • RCKT Health Care
  • VYX
  • Exchange
  • RCKT Nasdaq
  • VYX Nasdaq
  • Market Cap
  • RCKT 328.6M
  • VYX 1.8B
  • IPO Year
  • RCKT N/A
  • VYX N/A
  • Fundamental
  • Price
  • RCKT $3.17
  • VYX $13.15
  • Analyst Decision
  • RCKT Buy
  • VYX Strong Buy
  • Analyst Count
  • RCKT 13
  • VYX 5
  • Target Price
  • RCKT $12.96
  • VYX $14.20
  • AVG Volume (30 Days)
  • RCKT 2.8M
  • VYX 1.3M
  • Earning Date
  • RCKT 11-06-2025
  • VYX 11-06-2025
  • Dividend Yield
  • RCKT N/A
  • VYX N/A
  • EPS Growth
  • RCKT N/A
  • VYX N/A
  • EPS
  • RCKT N/A
  • VYX 7.32
  • Revenue
  • RCKT N/A
  • VYX $2,677,000,000.00
  • Revenue This Year
  • RCKT N/A
  • VYX N/A
  • Revenue Next Year
  • RCKT $108.43
  • VYX N/A
  • P/E Ratio
  • RCKT N/A
  • VYX $1.79
  • Revenue Growth
  • RCKT N/A
  • VYX N/A
  • 52 Week Low
  • RCKT $2.19
  • VYX $7.55
  • 52 Week High
  • RCKT $22.00
  • VYX $15.34
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 48.10
  • VYX 52.84
  • Support Level
  • RCKT $3.09
  • VYX $12.64
  • Resistance Level
  • RCKT $3.29
  • VYX $13.06
  • Average True Range (ATR)
  • RCKT 0.15
  • VYX 0.42
  • MACD
  • RCKT -0.02
  • VYX 0.00
  • Stochastic Oscillator
  • RCKT 37.94
  • VYX 59.48

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

About VYX NCR Voyix Corporation

NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.

Share on Social Networks: